DEERFIELD -- Baxter International said it will acquire Cheetah Medical, a provider of noninvasive hemodynamic monitoring technologies.
Under the deal, Baxter will pay $190 million in cash for the company, with potential for an additional $40 million based on clinical and commercial milestones.
Baxter officials said the addition of Cheetah Medical will accelerate its presence in specialized patient monitoring with technology used to guide fluid management. Cheetah Medical's technology focuses on fluid administration is data-driven and tailored to individual patient needs. Clinicians will be better able to manage patients with sepsis, acute kidney injury (AKI) and other critical conditions, as well as patients undergoing surgery, the company said in a statement.
Cheetah Medical, headquartered in Boston and Tel Aviv, Israel, has technology that is available in approximately 30 countries, including the United States. Cheetah Medical will provide Baxter with the company's noninvasive hemodynamic monitoring systems, including the latest Starling™ SV system.
"The robust capabilities and innovative monitoring technologies we will gain with the acquisition of Cheetah Medical will be additional strategic growth drivers as we work to eliminate preventable harm and enable personalized therapy for hospitalized patients around the world," said David Ferguson, general manager of Baxter's Medication Delivery division.
The acquisition is expected to close in the fourth quarter of 2019.